Neuronetics, Inc. is proud to announce the successful closing of an $18,000,000 funding round that will accelerate the growth of its innovative NeuroStar Advanced Therapy – the market leader in Transcranial Magnetic Stimulation (TMS) treatments for Major Depressive Disorder and other mental health conditions. Based in Malvern, PA, and a publicly traded medical device company under the ticker STIM, Neuronetics is committed to transforming patient care worldwide by providing accessible and effective neurohealth therapies. This capital infusion comes at an exciting time for the company, as it continues to solidify its leadership in a rapidly evolving mental healthcare landscape. With over 6.4 million NeuroStar treatments performed to date, NeuroStar remains the number one TMS option for doctors, offering a safe and non-invasive alternative to medication, shock therapy, or surgery. The company’s outpatient treatment, designed to be completed in as little as 20 minutes per session over a typical course of 36 sessions, leverages the science of neuroplasticity to directly target mental health challenges at their source—the brain.
The newly raised funds will be strategically funneled into scaling operations, enhancing clinical research, and broadening market access both within the United States and in select international territories. Neuronetics aims to further refine its advanced treatment protocols, ensuring that every patient receives the highest quality care at the right time. This investment also underscores the growing confidence in innovative approaches to mental health treatment and the significant potential of TMS technology to change lives. For more information or inquiries about NeuroStar Advanced Therapy, please visit NeuroStar.com/Safety or contact our dedicated support team.
